Hansa Biopharma AB (publ) (HNSBF) Discusses Top Line Results from PAES Study on Imlifidase in Highly Sensitized Kidney Transplant Patients Transcript
Hansa Biopharma AB has released the top line results from its PAES study on Imlifidase, a treatment for highly sensitized kidney transplant patients. The study aims to evaluate the efficacy and safety of Imlifidase in this specific patient population. The conference call included insights from key executives and researchers involved in the study.
- ▪Hansa Biopharma AB discussed the top line results from the PAES study on Imlifidase.
- ▪The study focuses on highly sensitized kidney transplant patients.
- ▪Key executives, including the CEO and Chief Medical Officer, participated in the conference call.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909278-hansa-biopharma-ab-publ-hnsbf-discusses-top-line-results-from-paes-study-on-imlifidase-in"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
